查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1983948

抗菌素抗药性监测市场：按交付方式、技术、应用和最终用户划分－2026-2032年全球预测

Antimicrobial Resistance Surveillance Market by Offering, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年抗菌药物抗药性监测市场价值为 63 亿美元，预计到 2026 年将成长至 66.7 亿美元，复合年增长率为 6.83%，到 2032 年将达到 100.1 亿美元。

主要市场统计数据
基准年 2025 63亿美元
预计年份：2026年 66.7亿美元
预测年份 2032 100.1亿美元
复合年增长率 (%) 6.83%

引人入胜的引言将抗菌素抗药性监测定位为一项紧迫的临床、技术和系统性挑战，需要综合诊断和数据。

抗菌药物抗药性监测处于临床紧迫性、技术进步和公共卫生策略的交汇点，需要持续有效地实施，并清晰地呈现挑战和不断变化的应对情况。引言部分概述了协作监测对于维持治疗效果至关重要的原因。细菌病原体抗药性的日益增强正在重塑诊断重点，加速了对快速表型和基因分型检测的需求，并迫使检查室和医疗保健系统重新思考如何在网络间收集、分析和共用数据。除了临床影响之外，监测系统在食品安全、环境监测和流行病学资讯方面也日益发挥核心作用，这扩大了相关人员的范围，并增加了对可互通资料标准和安全资讯交流的需求。

对重塑全球抗菌素抗药性监测系统的关键技术、营运和政策主导变革进行了深入分析。

抗菌药物抗药性监测领域正经历一场变革，其驱动力包括技术成熟、政策推动以及相关人员不断变化的期望。本节将详细阐述这项变革的关键驱动因素。快速表型检测和高通量定序的进步缩短了从检体采集到获得可操作资讯的时间，从而能够更精准地使用抗菌药物并及早发现新的抗药性模式。同时，数位健康平台和检查室资讯系统正在促进临床、公共卫生、食品安全和环境等领域之间更丰富的数据整合，从而强化了从孤立的检测事件向持续监测的转变。这些技术变革，加上监管力度的加强和对资料透明度日益增长的期望，正迫使各组织加强检验流程并投资于互通性标准。

对近期关税变化如何影响整个监控生态系统的采购趋势、供应弹性策略和营运计划进行全面评估。

2025年实施的关税措施的累积影响，为诊断试剂、其他试剂和实验室设备的采购计算引入了新的变数。本节将追踪这些措施的实际影响，而不依赖数值预测。进口关税的提高及相关贸易政策措施，加剧了依赖跨境供应链获取关键耗材和复杂设备的检查室和医疗系统的成本压力。为此，采购团队和供应商组织正日益重视货源多元化、本地生产伙伴关係以及库存优化策略，以减少对单一国家的依赖。同时，这些贸易变化也使得基于服务的交付模式和试剂租赁项目更具吸引力，因为它们可以作为缓衝机制，帮助医疗机构抵御资本支出波动带来的风险。

详细的细分洞察揭示了产品阵容、技术、应用和最终用户需求如何结合起来，决定监控优先顺序和采购行为。

关键的市场细分洞察揭示了产品、技术、应用和最终用户等维度如何相互交织，从而影响抗菌药物抗药性监测的采购重点、营运流程和投资选择。按产品划分，市场涵盖耗材和试剂、仪器、服务和软体。在耗材和试剂中，抗生素检测板、培养基和PCR试剂盒尤为突出，它们在监测过程中各自发挥特定作用，并具有各自的供应和检验要求。仪器涵盖了从手动抗菌药物敏感性试验（AST）台到全自动系统和质谱仪等多种平台。同时，服务和软体支援远端数据分析、品质保证以及将监测结果整合到临床决策支援系统中。

这项针对特定区域的分析揭示了特定区域的基础设施、采购框架和製造能力如何影响监测实施和供应商策略。

区域趋势对监测重点、供应链和诊断技术的应用曲线有显着影响。本节概述了关键区域的独特背景和战略意义。在美洲，完善的公共卫生基础设施和集中的参考检查室支援早期采用定序和自动化抗菌药物敏感性检测技术，而采购週期和报销机制则影响供应商的合作模式。此外，北美和南美之间的区域互联互通促进了集体爆发监测和数据共用的合作网络，这反过来又影响着供应商如何定位其整合硬体和软体解决方案以及服务产品。

切实可行的企业级洞察突显了整合平台、供应链韧性和伙伴关係模式如何重新定义监控解决方案的竞争优势。

抗菌素抗药性监测领域的企业正从单一产品策略转向整合硬体、试剂、资讯学和服务的一体化解决方案。本节概述了决定竞争地位的策略性倡议。领先的诊断和生命科学供应商正在投资模组化平台，以支援表型和基因型检测途径，从而帮助客户简化工作流程并降低复杂性。同时，试剂专家正在开发检验的检测组合，以简化监管合规流程并加速在各种实验室环境中的部署。随着互通性和数据分析成为寻求端到端监测能力的客户的关键差异化因素，仪器製造商和软体开发商之间的策略伙伴关係也日益普遍。

为高阶主管和职能领导提供实际有效的建议，以增强营运中监测的韧性、互通性和临床效用。

行业领导者必须采取有针对性、可操作的策略，将监测数据转化为营运韧性和临床影响。本节概述了一系列针对高阶主管和职能领导者的高效建议。首先，应优先考虑供应商多元化和合约机制，以确保关键耗材和备件的供应，而不是将组织束缚于单一供应商。与区域供应商建立关係并采用灵活的采购模式可以显着降低营运风险。其次，应投资可互通的资料架构和检验的分析方法，将检查室结果与临床和公共卫生系统连接起来。互通性能够实现更快的侦测、集中监控以及跨组织边界的协作回应。第三，应加快有针对性的自动化和数位化工作流程，将熟练人员从重复性工作中解放出来，同时提高可重复性和处理能力。将自动化与能力发展计画结合，可以保持人才储备。

我们透明且可重复的调查方法，结合了相关人员访谈、文献整合、专家检验和跨区域比较，为我们得出可靠的结论提供了支持。

本分析的调查方法结合了定性和定量方法，旨在得出稳健的、基于证据的结论，同时保持资料来源和检验过程的透明度。主要研究包括对检查室管理人员、采购负责人、临床微生物学家、公共卫生官员和技术供应商进行结构化访谈，以收集关于营运挑战、采购行为和技术应用障碍的第一手观点。此外，还对同行评审文献、监管指南、技术白皮书和已发表的临床检验研究进行了全面审查，这些研究详细阐述了检测方法的性能特征和工作流程整合方面的考虑因素。

总结整合工作，强调对技术、互通性和供应弹性进行协调投资，以保护治疗效果和公共卫生结果。

总之，抗菌素抗药性监测正从一系列独立的检查室活动转向一个协调一致、数据驱动的系统，涵盖临床护理、公共卫生、食品安全和环境监测。快速表型检测、定序和数位分析技术的进步使得监测讯号更加丰富，介入措施也更加迅速，但要充分发挥这些潜力，需要对互通性、人力资源能力和供应链韧性进行有意识的投资。政策变化、采购压力和不断演进的经营模式相互交织，要求各组织在短期营运连续性和长期能力建设之间取得平衡。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 抗菌素抗药性监测市场：依产品/服务分类

  • 耗材和试剂
    • 抗生素检测
    • 培养基
    • PCR试剂盒
  • 装置
  • 服务
  • 软体

第九章 抗菌素抗药性监测市场：依技术划分

  • 自动化AST系统
  • 手动AST
  • 质谱分析
  • 次世代定序
  • 即时PCR

第十章：抗菌素抗药性监测市场：依应用领域划分

  • 环境监测
  • 流行病学监测
  • 食品安全检查
  • 感染控制

第十一章 抗菌素抗药性监测市场：依最终用户划分

  • 学术研究机构
  • 临床检查室
  • 医院检查室
  • 製药和生物技术公司
  • 标准检验组织

第十二章 抗菌素抗药性监测市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 抗菌药物抗药性监测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 抗菌素抗药性监测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国抗菌素抗药性监测市场

第十六章：中国抗菌素抗药性监测市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Accelerate Diagnostics, Inc.
  • Alifax Srl
  • Becton, Dickinson and Company
  • bioMerieux SA
  • BioSpace, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • Liofilchem Srl
  • Lumed, Inc.
  • Luminex Corporation
  • Merck & Co., Inc.
  • Oxford Nanopore Technologies plc
  • Pfizer Inc.
  • QIAGEN NV
  • Seegene, Inc.
  • Siemens Healthineers AG
  • SyntBioLab, Inc.
  • T2 Biosystems, Inc.
  • Thermo Fisher Scientific, Inc.
  • Wolters Kluwer NV
Product Code: MRR-CF6C60CF95A8

The Antimicrobial Resistance Surveillance Market was valued at USD 6.30 billion in 2025 and is projected to grow to USD 6.67 billion in 2026, with a CAGR of 6.83%, reaching USD 10.01 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.30 billion
Estimated Year [2026] USD 6.67 billion
Forecast Year [2032] USD 10.01 billion
CAGR (%) 6.83%

A compelling introduction that frames antimicrobial resistance surveillance as an urgent clinical, technological, and systems-level priority requiring integrated diagnostics and data

Antimicrobial resistance surveillance sits at the intersection of clinical urgency, technological advancement, and public health strategy, requiring a coherent introduction that frames the challenge and the evolving response landscape. The opening assessment synthesizes why coordinated surveillance is foundational to preserving therapeutic efficacy: rising resistance profiles among bacterial pathogens are reshaping diagnostic priorities, accelerating demand for rapid phenotypic and genotypic testing, and forcing laboratories and health systems to reconsider how data is collected, analyzed, and shared across networks. In addition to clinical implications, surveillance systems are increasingly central to food safety, environmental monitoring, and epidemiological intelligence, thereby broadening the stakeholder base and amplifying requirements for interoperable data standards and secure information exchange.

Moreover, the contemporary introduction emphasizes the convergence of instrumentation, consumables, informatics, and services as integral components of an effective surveillance ecosystem. Diagnostic manufacturers, reagent suppliers, software developers, and service providers must coordinate to deliver integrated solutions that support real-time decision making. This introduction also acknowledges the operational pressures felt by laboratories, including workforce constraints, supply chain volatility, and regulatory requirements, while underscoring how investments in automation, sequencing, and analytics can enhance throughput and generate higher-fidelity surveillance signals. Ultimately, the introduction sets the stage for a report that balances technical detail with strategic implications, positioning surveillance as both a clinical necessity and a systems-level capability that demands sustained investment and cross-sector collaboration

Insightful analysis of the major technological, operational, and policy-driven shifts reshaping antimicrobial resistance surveillance systems worldwide

The landscape for antimicrobial resistance surveillance is undergoing transformative shifts driven by technological maturation, policy momentum, and changing stakeholder expectations, and this section details the principal vectors of change. Advances in rapid phenotypic testing and high-throughput sequencing have shortened the time from sample to actionable insight, enabling more precise antimicrobial stewardship and earlier detection of emerging resistance patterns. Concurrently, digital health platforms and laboratory information systems are enabling richer data linkages across clinical, public health, food safety, and environmental domains, reinforcing the shift from isolated testing events to continuous surveillance streams. These technological changes are complemented by growing regulatory scrutiny and heightened expectations for data transparency, prompting organizations to strengthen validation pathways and invest in interoperability standards.

In parallel, an operational recalibration is occurring across supply chains and service models. Laboratories are balancing in-house capability expansion with outsourced testing partnerships, while manufacturers are rethinking production flexibility and distribution strategies to mitigate supply disruptions. Workforce dynamics are also shifting: skilled laboratory professionals face increased demand, and organizations are deploying automation and remote-support models to preserve capacity. Taken together, these trends are not simply incremental; they are altering how surveillance programs are designed, funded, and operated. Decision-makers must therefore adapt governance models, invest in resilient supply relationships, and prioritize technologies that integrate seamlessly into existing clinical and public health workflows

Comprehensive evaluation of how recent tariff shifts are altering procurement dynamics, supply resilience strategies, and operational planning across surveillance ecosystems

The cumulative effect of tariff measures enacted in 2025 has introduced new variables into the procurement calculus for diagnostics, reagents, and laboratory instrumentation, and this section traces the practical implications without presuming numerical projections. Higher import duties and related trade policy measures have intensified the cost pressures on laboratories and health systems that rely on cross-border supply chains for critical consumables and complex instruments. In response, procurement teams and supplier organizations have increasingly prioritized diversification of sourcing, localized manufacturing partnerships, and inventory optimization strategies aimed at reducing single-country dependency. At the same time, these trade shifts have reinforced the attractiveness of service-based delivery models and reagent rental programs that can buffer facilities from capital expenditure volatility.

Regulatory and compliance burdens have also been affected, as increased tariffs may trigger adjustments in supplier contracts, customs processes, and lead-time expectations, necessitating more rigorous supplier performance monitoring and contractual protections. For manufacturers, the tariff environment has accelerated strategic decisions around regional manufacturing footprints and tariff engineering to preserve competitiveness. Health systems and reference labs are consequently adapting by strengthening demand forecasting, expanding collaborative purchasing consortia, and exploring homologation strategies to qualify alternative suppliers more rapidly. Importantly, these responses underscore a broader trend toward supply chain resilience and operational flexibility, where procurement agility and supplier transparency become as critical as product performance in sustaining effective antimicrobial resistance surveillance

In-depth segmentation insights revealing how product offerings, technologies, applications, and end-user needs collectively determine surveillance priorities and procurement behaviors

Key segmentation insights illuminate how distinct product, technology, application, and end-user dimensions intersect to shape procurement priorities, operational workflows, and investment choices within antimicrobial resistance surveillance. When examining the market by offering, the landscape spans consumables and reagents, instruments, services, and software; within consumables and reagents, attention centers on antibiotic panels, culture media, and PCR kits, each of which plays a specific role in surveillance pathways and has discrete supply and validation requirements. Instruments encompass a range of platforms from manual AST benches to fully automated systems and mass spec analyzers, while services and software enable remote data interpretation, quality assurance, and the integration of surveillance outputs into clinical decision support systems.

From a technology perspective, automated antimicrobial susceptibility testing systems, manual AST methods, mass spectrometry platforms, next-generation sequencing workflows, and real-time PCR assays present distinct trade-offs in turnaround time, sensitivity, and operational complexity. Applications drive adoption priorities differently: environmental monitoring emphasizes robust sample handling and throughput, epidemiological surveillance prioritizes data continuity and lineage tracing, food safety testing requires stringent traceability, and infection control focuses on rapid detection at the point of care or within hospital laboratories. End users further shape procurement and deployment models: academic and research institutes value configurability and depth of data, clinical laboratories and hospital laboratories prioritize throughput and regulatory compliance, pharmaceutical and biotechnology companies require stringent controls for development programs, and reference laboratories demand scalable, high-volume platforms. Understanding these segmentation dynamics is essential for aligning product development, commercialization strategies, and service models with the real-world needs of diverse stakeholders

Targeted regional analysis that clarifies how geographically specific infrastructure, purchasing frameworks, and manufacturing capabilities shape surveillance implementation and supplier strategies

Regional dynamics exert strong influence on surveillance priorities, supply chains, and the adoption curve for diagnostic technologies; this section synthesizes the distinct conditions and strategic implications across major geographies. In the Americas, established public health infrastructures and a concentration of reference laboratories support advanced adoption of sequencing and automated susceptibility testing, while procurement cycles and reimbursement frameworks shape supplier engagement models. Furthermore, regional interconnectivity in North and South America has prompted collaborative networks for outbreak detection and data sharing, which in turn influence how vendors position integrated hardware-software solutions and service offerings.

Across Europe, the Middle East and Africa, heterogeneity defines both challenge and opportunity. Well-resourced systems in parts of Western Europe have accelerated adoption of data-driven surveillance platforms and value digital interoperability, whereas resource-constrained settings in other parts of the region prioritize affordability, robustness, and ease of use. As a result, suppliers tailor portfolios to meet a wide spectrum of needs, often combining low-complexity, high-reliability assays with scalable software tools. In the Asia-Pacific region, diverse manufacturing capabilities, rapid technology diffusion, and significant investments in public health genomics create a dynamic marketplace for sequencing, real-time PCR, and automated AST solutions. Regional supply chain capabilities and domestic production policies also influence procurement choices, making local partnership strategies and flexible commercial models particularly effective for achieving deployment at scale

Actionable company-level insights highlighting how integrated platforms, supply resilience, and partnership models are redefining competitive advantage in surveillance solutions

Companies operating in the antimicrobial resistance surveillance space are evolving beyond single-product strategies toward integrated solution sets that combine hardware, reagents, informatics, and services, and this section distills the strategic moves that define competitive positioning. Leading diagnostic and life-science suppliers are investing in modular platforms that support both phenotypic and genotypic testing pathways, enabling clients to consolidate workflows and reduce complexity. At the same time, reagent specialists are developing validated assay panels that simplify regulatory compliance and accelerate deployment across heterogeneous laboratory environments. Strategic partnerships between instrument manufacturers and software developers are increasingly common, as interoperability and data analytics become critical differentiators for customers seeking end-to-end surveillance capabilities.

Additionally, many organizations are strengthening supply chain transparency and resilience through regional manufacturing, multi-sourcing strategies, and service contracts that bundle consumables with training and remote support. Sales and commercialization teams are adapting by offering flexible procurement models, including subscription and reagent-rental arrangements, which can lower adoption barriers for resource-constrained facilities. R&D priorities among companies reflect an emphasis on faster time-to-result, improved analytical sensitivity, and streamlined sample-to-answer workflows, while commercial strategies emphasize integrated clinical validation and health-economics evidence to support adoption. Together, these company-level trends signal a maturing market where technological breadth, supply reliability, and data integration increasingly determine competitive advantage

Practical, high-impact recommendations for executives and functional leaders to strengthen surveillance resilience, interoperability, and clinical utility across operations

Industry leaders must adopt focused, pragmatic strategies to translate surveillance intelligence into operational resilience and clinical impact, and this section outlines a set of high-impact recommendations tailored to senior executives and functional leaders. First, prioritize supplier diversification and contractual mechanisms that secure critical consumables and spare parts without locking organizations into single-source dependencies; building regional supplier relationships and embracing flexible procurement models can materially reduce operational risk. Second, invest in interoperable data architectures and validated analytics that connect laboratory outputs with clinical and public health systems; interoperability enables faster detection, centralized monitoring, and coordinated responses across institutional boundaries. Third, accelerate targeted automation and digital workflows that relieve skilled personnel from repetitive tasks while improving reproducibility and throughput; combine automation with competency development programs to maintain workforce depth.

Fourth, realign product and service portfolios around modular integration, ensuring that instruments, reagents, and software can be deployed in layered configurations that meet diverse end-user needs. Fifth, embed regulatory and quality assurance planning into product roadmaps to streamline approvals and enhance trust among clinical customers. Finally, foster collaborative models with public health agencies, academic centers, and industry partners to co-develop sentinel surveillance projects and pilot implementations; these collaborations generate operational evidence, validate real-world performance, and create pathways for scaled adoption. Implementing these recommendations requires disciplined governance, prioritized investment, and a focus on measurable outcomes tied to clinical utility and system resilience

Transparent and reproducible research methodology combining stakeholder interviews, literature synthesis, expert validation, and cross-regional comparison to support robust conclusions

The research methodology underpinning this analysis blends qualitative and quantitative approaches to ensure robust, evidence-based conclusions while maintaining transparency about data sources and validation processes. Primary research included structured interviews with laboratory leaders, procurement specialists, clinical microbiologists, public health officials, and technology vendors to capture first-hand perspectives on operational challenges, procurement behaviors, and technology adoption barriers. These insights were supplemented by a comprehensive review of peer-reviewed literature, regulatory guidance, technical whitepapers, and published clinical validation studies that detail assay performance characteristics and workflow integration considerations.

To ensure analytical rigor, findings were triangulated across multiple sources and subjected to expert validation rounds, where independent subject-matter experts reviewed assumptions, interpreted technical trade-offs, and assessed the operational feasibility of recommended actions. The methodology also incorporated cross-regional comparisons to highlight contextual differences and to identify where localized strategies are necessary. Limitations include variability in reporting standards across institutions and the evolving nature of regulatory pathways for new diagnostic modalities, which were addressed through conservative interpretation of qualitative data and transparent documentation of data provenance. Overall, the methodological approach emphasizes reproducibility, stakeholder validation, and the translation of technical evidence into actionable strategic guidance

Conclusive synthesis emphasizing coordinated investment in technology, interoperability, and supply resilience to protect therapeutic efficacy and public health outcomes

In conclusion, antimicrobial resistance surveillance is transitioning from a collection of discrete laboratory activities into a coordinated, data-driven system that spans clinical care, public health, food safety, and environmental monitoring. Technological advances in rapid phenotypic testing, sequencing, and digital analytics are enabling richer surveillance signals and faster interventions, but realizing this potential requires intentional investment in interoperability, workforce capacity, and supply chain resilience. The confluence of policy changes, procurement pressures, and evolving commercial models means that organizations must balance near-term operational continuity with longer-term capability building.

The synthesis underscores the importance of modular solutions that can be adapted to diverse laboratory settings, the necessity of diversified supplier strategies in the face of trade and tariff disruption, and the strategic value of integrated software and service offerings that translate raw data into actionable insights. Leaders who proactively align procurement, technology adoption, and governance will be better positioned to detect emerging resistance trends, support antimicrobial stewardship programs, and protect patient outcomes. This conclusion is a call to action for coordinated effort across manufacturers, laboratories, policymakers, and funders to prioritize surveillance as a foundational public health asset

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antimicrobial Resistance Surveillance Market, by Offering

  • 8.1. Consumables And Reagents
    • 8.1.1. Antibiotic Panels
    • 8.1.2. Culture Media
    • 8.1.3. PCR Kits
  • 8.2. Instruments
  • 8.3. Services
  • 8.4. Software

9. Antimicrobial Resistance Surveillance Market, by Technology

  • 9.1. Automated AST Systems
  • 9.2. Manual AST
  • 9.3. Mass Spectrometry
  • 9.4. Next Generation Sequencing
  • 9.5. Real Time PCR

10. Antimicrobial Resistance Surveillance Market, by Application

  • 10.1. Environmental Monitoring
  • 10.2. Epidemiological Surveillance
  • 10.3. Food Safety Testing
  • 10.4. Infection Control

11. Antimicrobial Resistance Surveillance Market, by End User

  • 11.1. Academic And Research Institutes
  • 11.2. Clinical Laboratories
  • 11.3. Hospital Laboratories
  • 11.4. Pharmaceutical And Biotechnology Companies
  • 11.5. Reference Laboratories

12. Antimicrobial Resistance Surveillance Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Antimicrobial Resistance Surveillance Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Antimicrobial Resistance Surveillance Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Antimicrobial Resistance Surveillance Market

16. China Antimicrobial Resistance Surveillance Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Accelerate Diagnostics, Inc.
  • 17.6. Alifax S.r.l.
  • 17.7. Becton, Dickinson and Company
  • 17.8. bioMerieux SA
  • 17.9. BioSpace, Inc.
  • 17.10. Bio-Rad Laboratories, Inc.
  • 17.11. F. Hoffmann-La Roche Ltd
  • 17.12. Illumina, Inc.
  • 17.13. Liofilchem S.r.l.
  • 17.14. Lumed, Inc.
  • 17.15. Luminex Corporation
  • 17.16. Merck & Co., Inc.
  • 17.17. Oxford Nanopore Technologies plc
  • 17.18. Pfizer Inc.
  • 17.19. QIAGEN N.V.
  • 17.20. Seegene, Inc.
  • 17.21. Siemens Healthineers AG
  • 17.22. SyntBioLab, Inc.
  • 17.23. T2 Biosystems, Inc.
  • 17.24. Thermo Fisher Scientific, Inc.
  • 17.25. Wolters Kluwer N.V.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ANTIBIOTIC PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ANTIBIOTIC PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ANTIBIOTIC PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CULTURE MEDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CULTURE MEDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CULTURE MEDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PCR KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PCR KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PCR KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY AUTOMATED AST SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY AUTOMATED AST SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY AUTOMATED AST SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MANUAL AST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MANUAL AST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MANUAL AST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY FOOD SAFETY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY FOOD SAFETY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY FOOD SAFETY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INFECTION CONTROL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INFECTION CONTROL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY INFECTION CONTROL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 128. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 129. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. GCC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. G7 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. G7 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 146. G7 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 147. G7 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. G7 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. G7 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. NATO ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. NATO ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 152. NATO ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 153. NATO ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. NATO ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. NATO ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)